Hassan Mir

Hassan Mir

Auto-generated profile, based on publicly available information

Hassan Mir

University of Ottawa Heart Institute Ottawa Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
HMHassan Mir
Hassan Mir
RSReed Alexander C Siemieniuk
Reed Alexander C Siemieniuk
LGLong Cruz Ge
Long Cruz Ge
FFFarid Foroutan
Farid Foroutan
MFMichael Fralick
Michael Fralick
GGGordon H Guyatt
Gordon H Guyatt
Objective To examine the relative impact of three management options in patients aged <60 years with cryptogenic stroke and a patent foramen ovale (PFO): PFO closure plus antiplatelet therapy, antiplatelet therapy alone and anticoagulation alone. Design Systematic review and network meta-analysis (NMA) supported by complementary external evidence. Data sources Medline, EMBASE and Cochrane CENTRAL. Study selection Randomised controlled trials (RCTs) addressing PFO closure and/or medical therapies in patients with PFO and cryptogenic stroke. Review methods We conducted an NMA complemented with external evidence and rated certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results Ten RCTs in eight studies proved eligible (n=4416). Seven RCTs (n=3913) addressed PFO closure versus medical therapy. Of these, three (n=1257) addressed PFO closure versus antiplatelet therapy, three (n=2303) addressed PFO closure versus mixed antiplatelet and anticoagulation therapies and one (n=353) addressed PFO closure versus anticoagulation. The remaining three RCTs (n=503) addressed anticoagulant versus antiplatelet therapy. PFO closure versus antiplatelet therapy probably results in substantial reduction in ischaemic stroke recurrence (risk difference per 1000 patients over 5 years (RD): −87, 95% credible interval (CrI) −100 to −33; moderate certainty). Compared with anticoagulation, PFO closure may confer little or no difference in ischaemic stroke recurrence (low certainty) but probably has a lower risk of major bleeding (RD −20, 95% CrI −27 to −2, moderate certainty). Relative to either medical therapy, PFO closure probably increases the risk of persistent atrial fibrillation (RD 18, 95% CI +5 to +56, moderate certainty) and device-related adverse events (RD +36, 95% CI +23 to +50, high certainty). Anticoagulation, compared with antiplatelet therapy, may reduce the risk of ischaemic stroke recurrence (RD −71, 95% CrI −100 to +17, low certainty), but probably increases the risk of major bleeding (RD +12, 95% CrI −5 to +65, moderate certainty). Conclusions In patients aged <60 years, PFO closure probably confers an important reduction in ischaemic stroke recurrence compared with antiplatelet therapy alone but may make no difference compared with anticoagulation. PFO closure incurs a risk of persistent atrial fibrillation and device-related adverse events. Compared with alternatives, anticoagulation probably increases major bleeding. PROSPERO registration number CRD42017081567.

1 April 2017 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
PDF file
DADarryl A. Auston
Darryl A. Auston
JMJordan Meiss
Jordan Meiss
RSRafael Serrano
Rafael Serrano
TSThomas Sellers
Thomas Sellers
GCGregory Carlson
Gregory Carlson
HMHassan R. Mir
Hassan R. Mir
Objective: To compare the incidence of complications (wound, infection, and nonunion) among those patients treated with closed, percutaneous, and open intramedullary nailing for closed tibial shaft fractures. Design: Retrospective review. Setting: Multiple trauma centers. Patients: Skeletally mature patients with closed tibia fractures amenable to treatment with an intramedullary device. Intervention: Intramedullary fixation with closed, percutaneous, or open reduction. Main Outcome Measurements: Superficial wound complication, deep infection, nonunion. Results: A total of 317 tibial shaft fractures in 315 patients were included in the study. Two-hundred fractures in 198 patients were treated with closed reduction, 61 fractures in 61 patients were treated with percutaneous reduction, and 56 fractures in 56 patients were treated with formal open reduction. The superficial wound complication rate was 1% (2/200) for the closed group, 1.6% (1/61) for the percutaneous group, and 3.6% (2/56) for the open group with no statistical difference between the groups (P = 0.179). The deep infection rate was 2% (4/200) for the closed group, 1.6% (1/61) for the percutaneous group, and 7.1% (4/56) for the open group with no significant difference between the groups (P = 0.133). Nonunion rate was 5.0% (10/200) for the closed group, 4.9% (3/61) for the percutaneous group, and 7.1% (4/56) for the open group, with no statistical difference between the groups (P = 0.492). Conclusions: This is the largest reported series of closed tibial shaft fractures nailed with percutaneous and open reduction. Percutaneous or open reduction did not result in increased wound complications, infection, or nonunion rates. Carefully performed percutaneous or open approaches can be safely used in obtaining reduction of difficult tibial shaft fractures treated with intramedullary devices. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

26 February 2025 in Tobacco Control
Verified
Journal Article
Open access
PDF file
MJMojgan Javad
Mojgan Javad
APAvinash Pandey
Avinash Pandey
JBJoseph Benjamen
Joseph Benjamen
MFMuhammad Furqan
Muhammad Furqan
MSMuhammad Salman
Muhammad Salman
HMHassan Mir
Hassan Mir
Objective Electronic nicotine delivery systems (ENDS), such as e-cigarettes, have surged in popularity. While long-term risks remain unclear, known dangers include nicotine addiction, E-cigarette or Vaping Use-Associated Lung Injury and potential extrapulmonary effects on the heart, immune system and neurodevelopment. Addressing ENDS addiction may require strategies akin to smoking cessation. However, evidence is lacking; there are no currently approved vaping-cessation aids. The objective of this review is to summarise the available literature addressing interventions for vaping cessation. Data sources and study selection A librarian-assisted search was conducted in MEDLINE, Embase and Scopus, as well as preprints in Europe PMC, Open Science Framework, and the grey literature searches until January 2024. Six included studies used self-report methods to determine the abstinence rate, while one study used cotinine-level-verified self-reported abstinence. We included randomised controlled trials (RCTs) that examine ‘rates of vaping cessation’ outcomes. An intention-to-treat approach was used for data extraction, and random-effects meta-analyses models were applied. Data synthesis Seven RCTs were included, which studied pharmacological therapy, digital interventions and/or educational content. The primary meta-analyses demonstrated a statistically significant increase in the odds of achieving 7-day point prevalence abstinence (PPA) (OR 1.52, 95% CI 1.15 to 2.01, number of participants=3244, moderate-certainty) and continuous abstinence (OR 2.71, 95% CI 1.31 to 5.61, number of participants=164, low-certainty) following intervention. A non-significant increase in odds was noted at 30-day PPA (OR 1.32, 95% CI 0.72 to 2.42, number of participants=1994, very low certainty). Conclusions Vaping cessation interventions increase 7-day PPA rates at 1–12 months follow-up and this was consistent across prespecified subgroup analyses of the intervention type, outcome and duration of follow-up. More high-quality studies with reproducible findings are needed to enhance the certainty of the evidence and guide clinical interventions. PROSPERO registration number CRD42022383670.

24 September 2023 in Obesity Pillars
Verified
Journal Article
Open access
IPIan Patton
Ian Patton
XSXimena Ramos Salas
Ximena Ramos Salas
BHBrad Hussey
Brad Hussey
MPMegha Poddar
Megha Poddar
Sanjeev SockalingamSanjeev Sockalingam
Sanjeev Sockalingam
CVCandace Vilhan
Candace Vilhan
Approximately 15% of Canadian adults live with two or more chronic diseases, many of which are obesity related. The degree to which Canadian obesity treatment guidelines are integrated into chronic disease management is unknown. We conducted a 12-min online survey among a non-probability sample of 2506 adult Canadians who met at least one of the following criteria: 1) BMI ≥30 kg/m2; 2) medical diagnosis of obesity; 3) undergone medically supervised treatment for obesity; or 4) a belief that excess/abnormal adipose tissue impairs their health. Participants must have been diagnosed with at least one of 12 prevalent obesity-related chronic diseases. Data analysis consisted of descriptive statistics. One in four (26.4%) reported a diagnosis of obesity, but only 9.2% said they had received medically supervised obesity treatment. The majority (55%) agreed obesity makes managing their other chronic diseases challenging; 39% agreed their chronic disease(s) have progressed or gotten worse because of their obesity. While over half (54%) reported being aware that obesity is classified as a chronic disease, 78% responded obesity was their responsibility to manage on their own. Only 33% of respondents responded they have had success with obesity treatment. While awareness of obesity as a chronic disease is increasing, obesity care within the context of a wider chronic disease management model is suboptimal. More work remains to be done to make Canadian obesity guidelines standard for obesity care.

26 September 2025 in Addiction
Verified
Journal Article
Open access
MJMojgan Javad
Mojgan Javad
SSSpencer Shahen
Spencer Shahen
EBEmma Lynn Bates
Emma Lynn Bates
SVSarah Visintini
Sarah Visintini
EQEvyanne Quirouette
Evyanne Quirouette
HMHassan Mir
Hassan Mir
Background and aims: Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited. This review aimed to evaluate the potential clinical effects of NPs in the context of smoking cessation, specifically focusing on user satisfaction, smoking urges and cigarette reduction compared with other nicotine and tobacco products.Design: Systematic review of randomized trials conducted in adult smokers or nicotine users, reported according to PRISMA 2020 guidelines and registered in PROSPERO.Setting: Studies conducted in high‐income countries across Europe and North America were included, with data collected up to March 2024.Participants/cases: Seven trials involving a total of 269 adult participants (≥18 years), including current smokers and users of other nicotine products. The review focused on tobacco‐free NPs containing varying nicotine strengths and flavors. NPs were compared individually to multiple specific comparators across trials, including cigarettes, snus, nicotine gum and placebo, rather than being combined into a single comparator group.Measurements: The primary outcomes were user satisfaction, urges to smoke and changes in cigarette consumption, considered the most important outcomes for assessing the potential of NPs in smoking cessation.Findings: NPs were rated more favorably for satisfaction and product liking than gum or placebo, but consistently less than cigarettes (e.g. intent to reuse 14–46% for NPs vs. 57% for cigarettes). In one pilot randomized controlled trial, daily cigarette use decreased from 15.0 to 8.3 cigarettes/day over 8 weeks with 4 mg NPs (P = 0.01), with dependence scores also reduced (3.1 to 2.4, P = 0.02). Across studies (n = 7, sample sizes 24–63), none demonstrated a statistically significant increase in smoking cessation compared with control, snus or gum. Adverse events were mostly mild (e.g. cough, throat irritation, headache) and more frequent at higher NP doses, but no serious adverse events were reported. Meta‐analysis was not performed due to heterogeneity in study designs and outcomes.Conclusions: Tobacco‐free nicotine pouches appear to be well tolerated and may reduce cigarette consumption compared with control, with effects similar to those seen with snus or nicotine gum. However, there is currently no statistically significant evidence that NPs increase rates of smoking cessation compared with other products or control.

22 October 2025 in Drug and Alcohol Dependence Reports
Verified
Journal Article
Open access
MJMojgan Javad
Mojgan Javad
EBEmma Lynn Bates
Emma Lynn Bates
SSSpencer Shahen
Spencer Shahen
SVSarah Visintini
Sarah Visintini
EQEvyanne Quirouette
Evyanne Quirouette
HMHassan Mir
Hassan Mir
Nicotine pouches (NP) are novel agents that deliver nicotine through buccal absorption as opposed to combustion. They are proposed as a harm reduction tool compared to smoking tobacco. However, there is limited evidence on their efficacy and safety. This review article summarizes the current evidence regarding NP pharmacokinetics compared to conventional tobacco products. We searched Medline, Embase, CENTRAL and Scopus for studies that assessed pharmacokinetic parameters of nicotine pouches. We identified studies involving tobacco-dependent adults and examined pharmacokinetic parameters such as total exposure, peak concentration, and time to peak. A meta-analysis was conducted using random-effects models to calculate pooled effect sizes. The Cochrane ROB 2.0 tool was used to evaluate the risk of bias in the included studies. A total of seven RCTs and crossover trials were included. Five compared NP pharmacokinetics with smoked tobacco, while two used moist snuff as comparators. Total nicotine exposure was significantly lower with 1.5 mg and 2 mg pouches, similar with 3.5 mg and 4 mg pouches, and significantly higher with pouches containing 8 mg or more when compared to cigarettes. A meta-analysis of three trials showed that 4 mg pouches delivered 91.73 % (95 % CI 85.03 %–98.42 %) of cigarette total nicotine exposure. Peak concentration was significantly lower with 1.5 mg, 2 mg, and 3.5 mg pouches while higher concentration pouches had greater peak when compared to cigarettes. A meta-analysis of three trials showed that 4 mg pouches showed a peak nicotine concentration of 69.15 % (95 % CI 58.55 %–79.76 %) compared with cigarettes. Peak nicotine concentration was consistently achieved earlier with cigarettes (5–8 min) than with pouches (20–65 min). Despite their buccal absorption, 4 mg pouches (most commonly used), deliver similar total nicotine exposure to cigarettes, though with lower peak concentrations and slower absorption. When combined with their flavours and aggressive marketing to youth, this raises concerns about the potential of nicotine pouches to cause nicotine dependence, especially among those using the product recreationally.